A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

Publication date: May 20, 2022

This Phase 1b/2a study will assess the efficacy, safety, and pharmacodynamics of CyPep-1 when administered directly into measurable tumor lesions in combination with the anti-PD-1 antibody pembrolizumab. Additionally, the study will assess anti-tumor effects of CyPep-1 on injected lesions and non-injected target lesions identified at baseline, as well as local and systemic immunological effects of CyPep-1 in combination with pembrolizumab.

Concepts Keywords
Childbearing Pharmacodynamics
Daily Radiation
Drugs Radiation therapy
Salpingectomy Pembrolizumab
Cancer immunotherapy
Immune system
Orphan drugs
Breakthrough therapy
Cancer treatments
Clinical medicine

Semantics

Type Source Name
disease MESH bundle branch block
disease MESH atrial fibrillation
disease MESH Torsade de Pointes
disease MESH Brugada syndrome
disease MESH short QT syndrome
disease MESH carcinomatous meningitis
disease MESH Castleman Disease
disease MESH Kaposi sarcoma
disease MESH interstitial lung disease
disease MESH pneumonitis
disease MESH hypothyroidism
disease MESH hypersensitivity
drug DRUGBANK Heparin
drug DRUGBANK Prothrombin
drug DRUGBANK Prednisone
disease MESH pituitary insufficiency
disease MESH skin cancer
disease MESH autoimmune disease
pathway KEGG Melanoma
disease MESH melanoma
disease MESH carcinomas
disease MESH carcinoma in situ
disease MESH metastasis
drug DRUGBANK Denosumab
pathway REACTOME SARS-CoV-2 Infection
disease MESH infection
disease MESH COVID-19
disease MESH amenorrhea
disease MESH biopsy
disease MESH Cancers
drug DRUGBANK Pembrolizumab

Original Article

Leave a Comment

Your email address will not be published.